Fluid-Screen is revolutionizing the way to analyze bacteria, challenging the status quo, bacterial culture, that has been a standard for quality assurance in the pharma industry for over 130 years. At Fluid-Screen we believe that people and companies make better decisions when they have access to the right information. These decisions impact their health, the well-being of their families, enabling them to work more efficiently. Our artificial intelligence-based microchip technology provides information about bacteria present in fluid samples in minutes instead of days. We help our partners, pharmaceutical companies, accelerate development and manufacturing of new therapeutics. It is time they get access to the right information when they need it. Fluid-Screen has raised over 7 million USD Series A round of financing. Our goal is to bring a family of products to market that will fundamentally improve the pharmaceutical manufacturing process. We are currently engineering our first prototype systems which will be deployed for validation testing at up to five identified customers.